Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

LRP1B mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

LRP1B mutation	Diffuse Large B Cell Lymphoma	LRP1B mutation	Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials nivolumab + ibrutinib Sensitive : C3	nivolumab + ibrutinib Sensitive: C3 – Early Trials nivolumab + ibrutinib Sensitive : C3
LRP1B mutation	Diffuse Large B Cell Lymphoma	LRP1B mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
LRP1B mutation	Non Small Cell Lung Cancer	LRP1B mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
LRP1B mutation	Endometrial Cancer	LRP1B mutation	Endometrial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LRP1B mutation	Endometrial Cancer	LRP1B mutation	Endometrial Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LRP1B mutation	Non Small Cell Lung Cancer	LRP1B mutation	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LRP1B mutation	Non Small Cell Lung Cancer	LRP1B mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LRP1B mutation	Prostate Cancer	LRP1B mutation	Prostate Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LRP1B mutation	Prostate Cancer	LRP1B mutation	Prostate Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LRP1B mutation	Renal Cell Carcinoma	LRP1B mutation	Renal Cell Carcinoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LRP1B mutation	Renal Cell Carcinoma	LRP1B mutation	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LRP1B mutation	Solid Tumor	LRP1B mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
LRP1B mutation	Hepatocellular Cancer	LRP1B mutation	Hepatocellular Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
LRP1B mutation	Non Small Cell Lung Cancer	LRP1B mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
LRP1B mutation	Lung Adenocarcinoma	LRP1B mutation	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3